Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

281. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial Full Text available with Trip Pro

Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial Limited data are available on the impact of renal function on the outcome of patients with atrial fibrillation (AF).AMADEUS was a multicentre, randomized, open-label non-inferiority study that compared fixed-dose idraparinux with conventional anticoagulation by dose-adjusted vitamin K antagonists. We performed a post hoc analysis to assess the impact of renal function on the outcomes (...) of anticoagulated AF patients. The primary efficacy outcome was the composite of stroke/systemic embolism (SE). The principal safety outcome of this analysis was major bleeding. We calculated c-indexes, reflecting the ability for discriminating diseased vs. non-diseased patients, and the net reclassification improvement (NRI, an index of inferior/superior performance of risk estimation scores). Of 4576 patients, 45 strokes and 103 major bleeding events occurred following an average follow-up of 325 ± 164 days

2013 EvidenceUpdates Controlled trial quality: uncertain

282. Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis

Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis – Clinical Correlations Search Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis June 28, 2013 7 min read By Sunny N. Shah, MD Faculty Peer Reviewed Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia and its (...) of ischemic stroke which is increased by greater than five-fold in patients with . (8) Given these results, the current American Heart Association/American College of Cardiology/European Society of Cardiology guidelines for the management of AF recommend the use of anticoagulation based on a patient’s risk of ischemic stroke. This risk is determined using known risk factors such as those identified by the CHA2DS2-VASc scoring system. (9) These guidelines thus give a Class IA recommendation

2013 Clinical Correlations

283. Scores poorly predict major bleeding (c-statistics ≤ 0.61) during oral anticoagulant therapy. (Abstract)

Scores poorly predict major bleeding (c-statistics ≤ 0.61) during oral anticoagulant therapy. 23553040 2013 05 13 2013 04 04 1539-3704 158 6 2013 Mar 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Scores poorly predict major bleeding (c-statistics ≤ 0.61) during oral anticoagulant therapy. JC13 10.7326/0003-4819-158-6-201303190-02013 White Richard H RH University of California, Davis Sacramento, California, USA. eng Comment Journal Article United States Ann Intern Med

2013 Annals of Internal Medicine

284. A Systematic Review: New Oral Anticoagulants vs Standard Anticoagulant Regimens for Thromboprophylaxis Related to Joint Replacement Surgery

A Systematic Review: New Oral Anticoagulants vs Standard Anticoagulant Regimens for Thromboprophylaxis Related to Joint Replacement Surgery Management Briefs Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management eBriefs: Provide VA senior managers with results from VA Health Services Research in a concise and timely manner

2013 Veterans Affairs - R&D

285. [New oral anticoagulants for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation]

[New oral anticoagulants for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation] Nuevos anticoagulantes orales para la prevencion del ictus y la embolia sistemica en fibrilacion auricular no valvular. [New oral anticoagulants for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation] Nuevos anticoagulantes orales para la prevencion del ictus y la embolia sistemica en fibrilacion auricular no valvular. [New oral anticoagulants (...) , Rodriguez Lopez R, Romero Tabares A, Beltran Calvo C, Molina Lopez T. Nuevos anticoagulantes orales para la prevencion del ictus y la embolia sistemica en fibrilacion auricular no valvular.. [New oral anticoagulants for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation] Seville: Andalusian Agency for Health Technology Assessment (AETSA). Informe 2/2012. 2012 Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulantss

2013 Health Technology Assessment (HTA) Database.

286. Warfarin vs New Oral Anticoagulants (NOACs) in Non-valvular AFib

Warfarin vs New Oral Anticoagulants (NOACs) in Non-valvular AFib Anticoagulation in Non-valvular 26 AFib www.RxFiles.ca COUMADIN PRADAXA XARELTO ELIQUIS LIXIANA SAVAYSA USA Warfarin Dabigatran 150mg Rivaroxaban Apixaban Edoxaban Stroke/Embolism ? 1 ??? 2 ?? 3 ??? 4 ??? 5 ICH X ? 6 ? 7 ? 8 ? 9 Major GI Bleed ? X 10 X 11 ? 12 X 13 Major Bleed ? ? 14 ? 15 ?? 16 ?? 17 Manage Bleed ? 14 ? 18 X? X? X? MI ? X? 19 -? -? -? DC Rate / Dyspepsia - X 20 /?GI - ? - Low renal fx (CrCl) ?? 21 CI 70%. 1 (...) ); higher with Dabi (NNH=25/~2yr); also more dyspepsia with Dabi (NNH=18/2yr). 21) All new agents lack study & experience in patients with decreased renal Fx. Dabi is contraindicated (CI) if CrCl <30ml/min. Warfarin can be used. Since AFib patients often older, impaired renal Fx an issue. 22) Economic review found new anticoagulants more costly than warfarin even after consideration for cost of INR monitoring was built in. However, “soft” indirect costs (e.g. time/travel to the patient) not included

2013 RxFiles

287. Patient self-monitoring of oral anticoagulation therapy

Patient self-monitoring of oral anticoagulation therapy File Name: 20130711 AS OAC v1.0 Version: 1.0 Date: 20 December 2013 Produced by: SHTG Page: 1 Review date: July 2014 Advice Statement 007/13 July 2013 Is patient self-monitoring (including self-testing and self- management) of oral anticoagulation therapy safe, efficacious and cost-effective? This advice has been produced following completion of evidence note 50 by Healthcare Improvement Scotland (update of evidence note 27) SHTG advises (...) that: ? Well conducted meta-analyses of randomised controlled trials (RCTs) in adults receiving long-term oral anticoagulation therapy with vitamin K antagonists reported that self-monitoring (encompassing self-testing or self-management) of International Normalised Ratio (INR) reduced the rate of thromboembolic events, compared with usual care, without increasing the rate of major bleeding events or mortality. ? Where measured, the majority of studies reported better quality of life outcomes for patient

2013 SHTG Advice Statements

288. Pacemaker or defibrillator surgery without interruption of anticoagulation. Full Text available with Trip Pro

Pacemaker or defibrillator surgery without interruption of anticoagulation. Many patients requiring pacemaker or implantable cardioverter-defibrillator (ICD) surgery are taking warfarin. For patients at high risk for thromboembolic events, guidelines recommend bridging therapy with heparin; however, case series suggest that it may be safe to perform surgery without interrupting warfarin treatment. There have been few results from clinical trials to support the safety and efficacy (...) of this approach.We randomly assigned patients with an annual risk of thromboembolic events of 5% or more to continued warfarin treatment or to bridging therapy with heparin. The primary outcome was clinically significant device-pocket hematoma, which was defined as device-pocket hematoma that necessitated prolonged hospitalization, interruption of anticoagulation therapy, or further surgery (e.g., hematoma evacuation).The data and safety monitoring board recommended termination of the trial after the second

2013 NEJM Controlled trial quality: predicted high

289. Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Full Text available with Trip Pro

Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Aspirin given for up to 2 years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Article Text Nursing issues Randomised controlled trial Aspirin given for up to 2 years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Free Henry G Watson Statistics from Altmetric.com Implications for practice and research The use of aspirin to prevent recurrent venous

2013 Evidence-Based Nursing

290. New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?)

New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?) New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) - GOV.UK GOV.UK uses cookies to make the site simpler. or Search New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines. Published 11 December 2014 From: Therapeutic area: Contents Article (...) update September 2016: In November 2015, idarucizumab (Praxbind▼) was granted a European licence as a specific reversal agent for dabigatran. Idarucizumab is indicated for adults treated with dabigatran when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures, or in life-threatening or uncontrolled bleeding. Further information about this medicine is available on the website of the Article date: October 2013 Dabigatran (Pradaxa) is a potent, orally active

2013 MHRA Drug Safety Update

291. Evidence note 50: Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost-effective?

Evidence note 50: Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost-effective? Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost-effective? Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost-effective? Thompson, L Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Thompson, L. Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost-effective? Glasgow: Healthcare Improvement Scotland. 2013 Authors' conclusions • Meta-analyses of randomised controlled trials data in patients receiving long-term oral anticoagulation therapy

2013 Health Technology Assessment (HTA) Database.

292. [Effectiveness of patient self-testing and patient self-management of oral anticoagulation with vitamin K antagonists]

[Effectiveness of patient self-testing and patient self-management of oral anticoagulation with vitamin K antagonists] Efectividad de la automonitorización y autocontrol del tratamiento con anticoagulantes orales antagonistas de la vitamina K [Effectiveness of patient self-testing and patient self-management of oral anticoagulation with vitamin K antagonists] Efectividad de la automonitorización y autocontrol del tratamiento con anticoagulantes orales antagonistas de la vitamina K (...) [Effectiveness of patient self-testing and patient self-management of oral anticoagulation with vitamin K antagonists] Llanos-Méndez A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Llanos-Méndez A. Efectividad de la automonitorización y autocontrol del tratamiento con anticoagulantes orales antagonistas de la vitamina K. [Effectiveness of patient

2013 Health Technology Assessment (HTA) Database.

293. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. (Abstract)

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared with clopidogrel (...) plus aspirin.We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008, to November, 2011, adults receiving oral anticoagulants and undergoing PCI were assigned clopidogrel alone (double therapy) or clopidogrel plus aspirin (triple therapy). The primary outcome was any bleeding episode within 1 year of PCI, assessed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769938.573 patients were

2013 Lancet Controlled trial quality: predicted high

294. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach Full Text available with Trip Pro

Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach Migliaccio-Walle K, Rublee D, Simon TA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the relative cost-effectiveness of new anticoagulants for preventing venous thromboembolism in patients undergoing elective total hip or knee arthroplasty in the UK. The authors concluded that the efficiency of apixaban for hip surgery was very good, but the risk-benefit for rivaroxaban was less clear; dabigatran and enoxaparin were not good value for money. The study was not well

2013 NHS Economic Evaluation Database.

295. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study (Abstract)

Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study Clinical scores may help physicians to better assess the individual risk/benefit of oral anticoagulant therapy. We aimed to externally validate and compare the prognostic performance of 7 clinical prediction scores for major bleeding events during oral anticoagulation therapy.We followed 515 adult patients taking oral anticoagulants to measure the first major bleeding event over a 12-month (...) was poor, with the C statistic ranging from 0.54 to 0.61 and not significantly different from each other (P=.84). Only the Anticoagulation and Risk Factors in Atrial Fibrillation score performed slightly better than would be expected by chance (C statistic, 0.61; 95% confidence interval, 0.52-0.70). The performance of the scores was not statistically better than physicians' subjective risk assessments (C statistic, 0.55; P=.94).The performance of 7 clinical scoring systems in predicting major bleeding

2012 EvidenceUpdates

296. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

297. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism Management Briefs Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management eBriefs: Provide VA senior managers with results from VA Health Services Research in a concise

2012 Veterans Affairs - R&D

298. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials

Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

299. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial (Abstract)

Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial To evaluate the impact of a pharmacist-led warfarin patient self-management program on quality of life and anticoagulation control compared with management in a physician-led specialized anticoagulation clinic.Prospective, randomized, controlled, open-label trial.Tertiary care academic medical center.A total of 114 patients aged 18-75 years who were followed (...) at a specialized anticoagulation clinic, had received warfarin for at least 6 months, and were expected to continue warfarin for a minimum of 4 months.All patients attended an educational session on anticoagulation provided by a pharmacist. Patients randomized to the self-management group (58 patients) also received practical training to use the CoaguChek XS device and a self-management dosing algorithm. Patients in the control group (56 patients) continued to undergo standard management at the anticoagulation

2012 EvidenceUpdates Controlled trial quality: uncertain

300. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomised controlled trials

Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.